Understand the source comparison
SS-31 Mitochondrial Disease: Compound Comparison
SS-31 mitochondrial disease research exists within a broader landscape of mitochondrial-targeted therapies, each with distinct mechanisms, evidence bases, and practical limitations. The table below compares elamipretide against the most commonly studied altern
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-31 mitochondrial disease research exists within a broader landscape of mitochondrial-targeted therapies, each with distinct mechanisms, evidence bases, and practical limitations. The table below compares elamipretide against the most commonly studied alternatives.
- SS-31 (Elamipretide)
- Binds cardiolipin, stabilises cristae, inhibits cytochrome c peroxidase
- Phase 3 RCT (MMPOWER-3): +42.5m 6MWT vs placebo in PMM; ³¹P-MRS improvements in Barth syndrome
- High mitochondrial tropism due to membrane potential-driven accumulation
- Subcutaneous injection required; cost barrier outside clinical trials; short plasma half-life
- Only compound with Phase 3 evidence for functional improvement in genetic mitochondrial disease
- Idebenone
- Quinone analogue; accepts electrons from Complex I, bypasses downstream blockade
- Some efficacy in Leber's hereditary optic neuropathy (LHON); inconsistent results in Friedreich's ataxia
- Poor CNS penetration; predominantly hepatic and cardiac distribution
- Oral bioavailability ~15%; requires high doses (900mg/day); gastrointestinal side effects common
- Moderate evidence in LHON; limited utility in multi-system mitochondrial disease
- CoQ10 (Ubiquinone)
- Electron carrier in respiratory chain; ROS scavenger
- No placebo-controlled evidence of benefit in primary mitochondrial myopathy; anecdotal reports in CoQ10 deficiency syndromes
- Ubiquitous tissue distribution; does not preferentially accumulate in mitochondria
- Absorption highly variable; reduced form (ubiquinol) improves bioavailability modestly
- Standard-of-care supplementation despite absence of robust clinical trial support
- MitoQ
- Ubiquinone conjugated to triphenylphosphonium cation for mitochondrial targeting
- No published trials in primary mitochondrial disease; some data in Parkinson's disease (neutral results)
- Mitochondrial accumulation via membrane potential
- Expensive; oral bioavailability concerns; limited human safety data beyond Phase 2 trials
- Theoretically superior to CoQ10 due to targeting, but clinical validation lacking
- NAD+ precursors (NR, NMN)
- Restore NAD+ pools required for Complex I function and sirtuin activation
- Observational improvements in mitochondrial myopathy case series; no large RCTs
- Systemic NAD+ elevation affects multiple pathways beyond mitochondria
- Oral administration; no evidence of mitochondrial-specific NAD+ restoration
- Promising mechanistic rationale; insufficient clinical data to recommend over standard care
- The bottom line: SS-31 is the only intervention with Phase 3-level evidence demonstrating functional benefit in primary mitochondrial myopathy. Idebenone has niche utility in LHON but limited applicability to broader mitochondrial disease. CoQ10 remains widely used despite weak clinical support. Mitochondrial-targeted antioxidants like MitoQ and NAD+ precursors remain investigational.